Silo Pharma, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $72,102 | $72,102 | $72,102 | $72,102 | — |
| Cost of revenue | $44,295 | $5,838 | $5,838 | $5,838 | $5,004 |
| Gross profit | $27,807 | $66,264 | $66,264 | $66,264 | $66,260 |
| Selling, general & administrative | — | — | $390,071 | $227,259 | $162,953 |
| Research and development | $2.2M | $2.4M | $845,092 | $1.3M | $693,910 |
| Operating expenses | $4.3M | $4.8M | $3.9M | $3.7M | $2.8M |
| Operating income | -$4.3M | -$4.7M | -$3.9M | -$3.6M | -$2.7M |
| Interest expense | $37,302 | $5,084 | $4,869 | $2,199 | $3,036 |
| Pretax income | -$4.2M | -$4.4M | -$3.6M | -$3.9M | $4.2M |
| Income tax expense | — | — | — | $0 | $24,876 |
| Net income | -$4.2M | -$4.4M | -$3.7M | -$3.9M | $3.9M |
| Balance Sheet | |||||
| Cash and equivalents | $4.7M | $3.9M | $3.5M | $11.4M | $9.8M |
| Current assets | $7.4M | $7.1M | $7.7M | $11.6M | $10.4M |
| Total assets | $7.6M | $7.4M | $7.7M | $11.6M | $10.5M |
| Current liabilities | $650,183 | $1.7M | $775,590 | $436,318 | $490,039 |
| Total liabilities | $1.3M | $2.4M | $1.6M | $1.3M | $1.4M |
| Stockholders' equity | $6.3M | $5.0M | $6.2M | $10.3M | $9.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$4.7M | -$3.8M | -$3.2M | -$3.5M | -$2.3M |
| Stock-based compensation | $117,021 | $906,773 | $871,625 | $577,651 | $395,123 |
| Impairments | $39,916 | — | — | — | — |
Shares outstanding 16.3M · Free float 98.7%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.